Potential Susceptibility Mutations in C Gene for Hepatitis B-Related Hepatocellular Carcinoma Identified by a Two-Stage Study in Qidong, China.
PMID: 27727182
2016
International journal of molecular sciences
Abstract: A total of 10 mutations (including pre-S2 start codon mutation and pre-S deletion in pre-S gene, G1613A, C1653T, A1762T, and G1764A mutations in X gene, A2159G, A2189Y, G2203W, and C2288R mutations in C gene) showed an increased risk of HCC.
Abstract: In the validation study, pre-S deletion, C1653T, A1762T/G1764A
HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression.
Introduction: In addition to TA, other CP mutations, notably C1653T, T1674C/G, C1766T, T1753V and T1768A, have also been reported to be associated with an increased risk of HCC.
Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma.
Introduction: We and others have reported that HBV mutations C1653T, T1753V, A1762T/G1764A, T1674C/G, and C1766T/T1768A in the enhancer II/basal core promoter (EnhII/BCP) region; G1899A, C2002T, A2159G, A2189C, and G2203A/T in the precore/core region; as well as T53C, PMID: 25625002
2015
World journal of hepatology
Abstract: We previously demonstrated that the accumulation of >= 6 mutations at eight key nucleotides located in these regions (G1613A, C1653T, T1753V, A1762T, G1764A, A1846T, G1896A, and G1899A) is a useful marker to predict the development of HCC regardless of advanced liver disease.
The characteristic changes in hepatitis B virus x region for hepatocellular carcinoma: a comprehensive analysis based on global data.
Method: The following mutation sites were also detected in the included studies: G1613A, C1653T, 1752G, T1754V, T1753V/A1762T/G1764A, T1758C, G1764A/C1766T/T1768A, T1770A, 1773 T, G1775A, C1799V, T1800C, T1803C, G1809T, A1814C, A1837G, A1846G, T1853C, PMID: 26290395
2015
Cancer prevention research (Philadelphia, Pa.)
Abstract: In control patients carrying A1762T/G1764A, addition of C1653T and/or T1753V significantly increased HCC risk (HR, 1.57; P = 0.038); combo mutations with C1653T, T1753V, and A1762T/G1764A improved the validity of HCC prediction by age, male, and cirrhosis (P = 0.002).
Abstract: In summary, HBV mutation A1762T/G1764A, C1653T, and T1753V in combination improve PMID: 26568165
2015
Scientific reports
Method: A risk prediction model to classify the HCC cases and controls was constructed according to the following steps: (1) Prediction factor selection: HBV genotype, the 11 independent HCC-related mutations (C1653T, C1673T, T1674C/G, C1730G, A1752G, T1753C, A1762T, G1764A, G1899A, G1915A/C and C1969T), the HLA SNPs (rs9272105 and rs9275319), the HCC-related multiplicative interactions (rs9272105 with the HBV genotype,
G1896A Precore Mutation and Association With HBeAg Status, Genotype and Clinical Status in Patients With Chronic Hepatitis B.
Abstract: The basal core promoter mutations detected were A1762T-G1764A (26.9%), C1653T (8.6%), A1752G (10.8%) and C1766T (2.2%).
Result: Among the basal core promoter mutations, A1762T-G1764A double mutation was present in 26.9%, C1653T in 8.6%, A1752G in1 0.8% and C1766T in 2.2% of all isolates.
Table: C1653T
[Associations between hepatitis B virus x gene mutations and hepatocellular carcinoma].
Abstract: RESULTS: Mutations of G1467C, G/C1479A, C1485T and C1653T in the X region were found, but did not show any significant difference in occurrence between the HCC group and the chronic HBV infection group (P>0.05).
HBV mutation literature information.
PMID: 
2016
International journal of molecular sciences
Browser Board
Co-occurred Entities
Filtrator
ViMRT